Navigation Links
Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
Date:11/10/2008

Pivotal Phase 3 Clinical Trial For Duska's ATPace In Planning Stage

LA JOLLA, Calif. and PARSIPPANY, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc., (OTC Bulletin Board: DSKA) and DSM Pharmaceuticals, Inc., announced today that they have entered into a preliminary agreement to collaborate on the manufacture of commercial batches of ATPace for Duska's planned pivotal Phase 3 clinical trial in paroxysmal supraventricular tachycardia (PSVT). ATPace will be produced at DSM's commercial facilities in Greenville, North Carolina.

ATPace, a stable liquid formulation of adenosine 5'-triphosphate (ATP) for intravenous injection, is an investigational drug for the acute termination of PSVT. The bradycardic effect of ATP, in particular its blockade of atrio- ventricular nodal conduction, has been shown in numerous published clinical studies to safely and effectively terminate re-entrant PSVT involving the atrio-ventricular node. Design of a pivotal Phase 3 clinical trial for ATPace in PSVT is in the planning stage.

PSVT, one of the most common cardiac arrhythmias, is a rapid, regular heart rate originating in the atria. It has been estimated that there are 89,000 new cases of PSVT per year and approximately 570,000 persons with PSVT in the United States alone.

Currently, adenosine is the only approved treatment for PSVT in the United States. Duska believes that the initial dose of ATPace will be significantly more efficacious than the initial labeled dose of adenosine in terminating PSVT. While both ATP and adenosine inhibit atrio-ventricular nodal conduction, ATP is believed to have dual inhibitory action; one mediated by adenosine, the product of its rapid enzymatic degradation, and the other a triggered vagal reflex. Vagal maneuvers aimed at enhancing vagal tone to the heart, and thereby suppressing atrio-ventricular nodal conduction, have been clinically used to terminate tachycardia. Injectable formulations of ATP have b
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
2. Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
3. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
4. Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
5. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
6. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
7. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
8. Cornerstone Therapeutics Announces New Board of Directors
9. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
10. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
11. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Dr. Kwame Bawuah ... the workshop with an admonition to the youth to ... in life. He also advised the youth to stay ... sex. He said, “This workshop will afford you the ... you to withstand the storms in your career path.” ...
(Date:7/24/2014)... 24, 2014 The first-ever successful isolation ... patient’s blood has been achieved by NFCR-supported scientist Daniel ... Hospital. This is an important milestone on the road ... the best treatment for each patient. , “Tumors ... often acquire new genetic features that make them resistant ...
(Date:7/24/2014)... the patient or their tumor more directly to ionizing ... damages the cancer cells irreparably. Unfortunately, such radiation is ... the site of the tumor, which is then at ... cancer. As such finding ways to protect the overlying ... Journal of Low Radiation, Faruck Lukmanul Hakkim of the ...
(Date:7/24/2014)... have uncovered a way the malaria parasite becomes ... Washington University School of Medicine in St. Louis, ... bacterial infections and tuberculosis. , The study appears ... Many organisms, including the parasite that causes malaria, ... play multiple roles in keeping organisms healthy, whether ...
(Date:7/24/2014)... Charlotte, NC (PRWEB) July 24, 2014 ... donated over $138,000 in sealant and anesthesia reversal ... ToothFairy® (NCOHF) to help save young smiles. The ... Sealant Kits and Oraverse® was distributed to America’s ... the U.S. with vital oral health services. The ...
Breaking Medicine News(10 mins):Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:Natural products from plants protect skin during cancer radiotherapy 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3Health News:Septodont Donation Helps Children in Need 2
... responsible for a form of the herpes virus that causes ... causes purple skin blotches and can also attack the internal ... disease defenses but attacks those with weakened immune system as ... 8 was discovered six years ago. Almost 30% to 50% ...
... not reduce ,the risk of cardiac events ... disease (CAD). In the PHASE trial (Papworth ... women with angiographically proven coronary ,artery disease ... without cyclic norethisterone--or no hormone replacement therapy. ...
... Lunelle-a monthly injectable contraceptive pill has been approved by ... is more than 99 percent effective when women get ... release marketing the pill., ,Lunelle is an alternative ... months. It works Like many other birth control pills ...
... overall long-term survival rates in both men and women. Their ... ,Researchers studied survival rates based on a lung function ... the lung function test on a group of more than ... age from 20 to 89 years at enrollment. They have ...
... In some of the cancer patients the Tumors can't be ... using vitamin B12 that helps doctors locate hard to find ... vitamin B12. After three hours a gamma camera takes pictures ... cancer and he says that, "The cancer stands out as ...
... The American Heart Association announced it has revised ... of ,cardiovascular emergencies., ,Untrained bystanders and CPR-certified ... an unconscious person's pulse before administering chest compressions. ... breath, movement and response to stimulation as indicators. ...
Cached Medicine News:
(Date:7/24/2014)... -- Decision Resources Group finds that, for the treatment ... France , Germany , ... and the United Kingdom ) hold ... beta2 agonist/inhaled corticosteroid (LABA/ICS) fixed-dose combination (FDC), Relvar (GlaxoSmithKline/Theravance). ... first-line LABA/ICS FDC in the treatment of asthma with ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- "North America ... key market data on the North America Orthopedic Braces ... of US dollars, and volume (in units) and average ... , Knee Braces and Supports , Ankle ... , Upper Extremities Braces and Supports. ...
(Date:7/24/2014)... 24, 2014 Boston Children,s Hospital,s Global Pediatric ... will feature an "Innovation Tank" – a forum designed ... pitch their business or product solution to a panel ... on how to accelerate the innovation and bring it ... of Friday, October 31, will be moderated by ...
Breaking Medicine Technology:Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... 2011 /PRNewswire-Asia-FirstCall/ -- Financial Highlights for the ... increased 40.8% to $7.68 million Gross profit increased 30.1% to ... 14.2% to $3.90 million, representing a net margin of 50.8% ... Financial Highlights for the Six Months Ended June ...
... Mylan Inc. (Nasdaq: MYL ) today announced that ... Tablets, 10 mg. This product is the generic version of ... hyperplasia, or an enlarged prostate. Uroxatral® Tablets ... months ending June 30, 2011, according to IMS Health. ...
Cached Medicine Technology:Nutrastar Announces Second Quarter 2011 Financial Results 2Nutrastar Announces Second Quarter 2011 Financial Results 3Nutrastar Announces Second Quarter 2011 Financial Results 4Nutrastar Announces Second Quarter 2011 Financial Results 5Nutrastar Announces Second Quarter 2011 Financial Results 6Nutrastar Announces Second Quarter 2011 Financial Results 7Nutrastar Announces Second Quarter 2011 Financial Results 8Nutrastar Announces Second Quarter 2011 Financial Results 9Nutrastar Announces Second Quarter 2011 Financial Results 10Nutrastar Announces Second Quarter 2011 Financial Results 11
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: